Veenat 100mg tablets | Blueberry pharmaceuticals

50 %
50 %
Information about Veenat 100mg tablets | Blueberry pharmaceuticals

Published on June 6, 2019

Author: savanah


blueberrypharma: blueberrypharma VEENAT – 100MG Slide 2: DESCRIPTION Veenat   is a small molecule kinase inhibitor. Veenat film -coated tablets contain Imatinib mesylate . STI-571 is another name for  Veenat   and is a targeted therapy.  Veenat   is classified as a signal transduction inhibitor - protein-tyrosine kinase inhibitor Slide 3: Veenat 100mg  tablet is belongs to anti- neoplastic medicine which is indicated in the treatment of Advanced myelogenous leukemia (CML) and Gastrointestinal stromal tumors (GISTs) and several malignancies.  Veenat 100mg is indicated as single treatment, or it may have consolidated with some other drug in the conditions of some types of cancer or bone marrow disorders.   INDICATION Slide 4: PRESCRIBED FOR Veenat 100mg tablets are mainly indicated for the treatment of; Aggressive systemic mastocytosis . Chronic esinophillic leukemia. Dermatofibrosarcoma protuberans . Gastrointestinal stromal tumors. Hyperesinophillic syndrome. Myelodysplastic syndrome. Slide 5: DRUG INTERACTION Drug which inhibits the CYP3A4 activity may have chance to reduce metabolism and elevates the plasma concentration of  Veenat   frequently. Co administration of St. John’s wort with  Veenat   causes decreasing AUC of Veenat to 30%. To avoid this problem, the dosage of Veenat increases up to 1200mg /day (600mg as two times a day). While concomitant use of  Veenat   with strong inducers of CYP3A4, the dose of Veenat increased to 50%. If used with CYP3A4 strong inducers the AUC of Veenat decreases to 73%. Slide 6: FOR MORE INFORMATION CALL US : +91-97890 77748  MAIL TO : Domain :

Add a comment

Related presentations